Mizuho Securities reiterated a Buy rating for a Group A strep vaccine, noting benefits from Trump-era tariffs and onshoring trends.
1 report, 1 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Mizuho Securities reiterated a Buy rating for a Group A strep vaccine, noting benefits from Trump-era tariffs and onshoring trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Mizuho Securities
Japanese investment banking company
Nothing else this week.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
- Mizuho Securities lifted its price target and disclosed a transaction involving Guardant Health in an SEC filing.
- Mizuho Securities boosted its target price on Dominion Energy stock and filed with the SEC regarding stock purchases.
- Analysts from Royal Bank of Canada, Mizuho Securities, and Leerink partners issued rating and target price updates for Medtronic shares.
- Mizuho Securities boosted its rating on The Cheesecake Factory stock, which also filed with the SEC and trades on Nasdaq.
- Mizuho Securities, Royal Bank of Canada, and Citigroup raised their price targets and ratings for Welltower Inc. on September 5, 2026.